English
简体中文
Total: £ 56.28
Published Date: 2026-01-08 | Pages: 114 | Tables: 120 | Medical Care
The global Hepatocellular Carcinoma Treatment Drug market was valued at US$ 4850 million in 2025 and is anticipated to reach US$ 7796 million by 2032, at a CAGR of 7.0% from 2026 to 2032.
Hepatocellular carcinoma (HCC) treatment drugs refer to various systemic therapeutic agents used to inhibit tumor growth, prolong patient survival, or improve quality of life. These drugs exert their anti-tumor effects by blocking tumor angiogenesis, regulating signaling pathways, or activating the body's immune system. They are suitable for patients with unresectable or advanced HCC and have become the core means of current systemic treatment for liver cancer. The upstream of the HCC treatment drug industry chain mainly includes raw material (API) suppliers, key intermediate synthesis companies, biological reagent and cell culture consumable manufacturers, and R&D and manufacturing outsourcing organizations that provide CRO (Contract Research Organization) and CDMO (Contract Development and Manufacturing Organization) services. The midstream consists of innovative pharmaceutical companies and biotechnology companies responsible for target discovery, preclinical research, clinical trials, and drug registration. Representative companies include Roche, Merck, BeiGene, and Hengrui Medicine. The downstream covers hospitals, oncology centers, DTP pharmacies, and medical insurance/commercial insurance payment systems, and achieves commercialization through academic promotion, access negotiations, and patient assistance programs. Since these drugs are mostly high-barrier patented innovative drugs or biologics, they have strong pricing power. The gross profit margin of major global products is generally as high as 80%-90%. Even under the pressure of centralized procurement or medical insurance negotiations, the gross profit margin of core HCC drugs of leading domestic companies can still be maintained at more than 75%, which is significantly higher than that of ordinary generic drugs.
The hepatocellular carcinoma treatment drug market is supported by rising global liver cancer incidence, aging populations, and improved diagnostic capabilities. Targeted therapies and immuno-oncology drugs are increasingly replacing conventional chemotherapy due to superior efficacy and better patient tolerance. Combination therapy strategies are becoming mainstream, driving higher treatment value per patient. Strong pricing power and high gross margins reflect significant R&D investment and regulatory barriers. Emerging markets contribute incremental volume growth as access to oncology care improves. Overall, the market is expected to maintain stable expansion, driven by innovation, clinical guideline updates, and expanding reimbursement coverage.
This report delivers a comprehensive overview of the global Hepatocellular Carcinoma Treatment Drug market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Hepatocellular Carcinoma Treatment Drug. The Hepatocellular Carcinoma Treatment Drug market size, estimates, and forecasts are provided in terms of revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global Hepatocellular Carcinoma Treatment Drug market comprehensively. Regional market sizes by Type, by Application, by Treatment Line, and by player are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Hepatocellular Carcinoma Treatment Drug manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation
By Company
Merck & Co.
Bayer
Roche
Eli Lilly and Company
Bristol-Myers Squibb
Exelixis Inc
Innovent Biologics Inc
Akeso, Inc
Jiangsu Hengrui Medicine Co Ltd
AstraZeneca Plc
BeiGene
Sanofi SA
Segment by Type
Targeted Therapy Drugs
Immune Checkpoint Inhibitors
Chemotherapy Drugs
Segment by Treatment Line
First-line HCC Therapy
Second-line HCC Therapy
Adjuvant Therapy
Palliative Drug Treatment
Segment by Administration Route
Oral HCC Drugs
Intravenous Infusion Drugs
Intra-arterial Chemotherapy Drugs
Segment by Application
Below 29 Years
30-49 Years
Above 50 Years
By Region
North America
U.S.
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia & New Zealand
Rest of Asia
Europe
Germany
France
U.K.
Italy
Ireland
Russia
Rest of Europe
Latin America
Mexico
Brazil
Argentina
Rest of Latin America
Middle East & Africa
Israel
United Arab Emirates (UAE)
Saudi Arabia
Rest of MEA
Chapter Outline
Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, by Treatment Line, etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Summarizes global and regional market size and outlines market dynamics and recent developments, including key drivers, restraints, challenges and risks for industry participants, and relevant policy analysis.
Chapter 3: Provides a detailed view of the competitive landscape for Hepatocellular Carcinoma Treatment Drug companies, covering revenue share, development plans, and mergers and acquisitions.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify blue-ocean opportunities.
Chapter 5: Analyzes segments by Application, detailing the size and growth potential of each downstream segment to help readers identify blue-ocean opportunities.
Chapter 6–10: Regional deep dives (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) broken down by country. Each chapter quantifies market size and growth potential by region and key countries, and outlines market development, outlook, addressable space, and capacity.
Chapter 11: Profiles key players, presenting essential information on leading companies, including product/ service offerings, revenue, gross margin, product introductions/portfolios, recent developments, etc.
Chapter 12: Key findings and conclusions of the report.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Hepatocellular Carcinoma Treatment Drug Market Size Growth Rate by Type: 2021 vs 2025 vs 2032
1.2.2 Targeted Therapy Drugs
1.2.3 Immune Checkpoint Inhibitors
1.2.4 Chemotherapy Drugs
1.3 Market by Treatment Line
1.3.1 Global Hepatocellular Carcinoma Treatment Drug Market Size Growth Rate by Treatment Line: 2021 vs 2025 vs 2032
1.3.2 First-line HCC Therapy
1.3.3 Second-line HCC Therapy
1.3.4 Adjuvant Therapy
1.3.5 Palliative Drug Treatment
1.4 Market by Administration Route
1.4.1 Global Hepatocellular Carcinoma Treatment Drug Market Size Growth Rate by Administration Route: 2021 vs 2025 vs 2032
1.4.2 Oral HCC Drugs
1.4.3 Intravenous Infusion Drugs
1.4.4 Intra-arterial Chemotherapy Drugs
1.5 Market by Application
1.5.1 Global Hepatocellular Carcinoma Treatment Drug Market Growth by Application: 2021 vs 2025 vs 2032
1.5.2 Below 29 Years
1.5.3 30-49 Years
1.5.4 Above 50 Years
1.6 Assumptions and Limitations
1.7 Study Objectives
1.8 Years Considered
2 Global Growth Trends
2.1 Global Hepatocellular Carcinoma Treatment Drug Market Perspective (2021–2032)
2.2 Global Hepatocellular Carcinoma Treatment Drug Growth Trends by Region
2.2.1 Global Hepatocellular Carcinoma Treatment Drug Market Size by Region: 2021 vs 2025 vs 2032
2.2.2 Hepatocellular Carcinoma Treatment Drug Historic Market Size by Region (2021–2026)
2.2.3 Hepatocellular Carcinoma Treatment Drug Forecasted Market Size by Region (2027–2032)
2.3 Hepatocellular Carcinoma Treatment Drug Market Dynamics
2.3.1 Hepatocellular Carcinoma Treatment Drug Industry Trends
2.3.2 Hepatocellular Carcinoma Treatment Drug Market Drivers
2.3.3 Hepatocellular Carcinoma Treatment Drug Market Challenges
2.3.4 Hepatocellular Carcinoma Treatment Drug Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Hepatocellular Carcinoma Treatment Drug Players by Revenue
3.1.1 Global Top Hepatocellular Carcinoma Treatment Drug Players by Revenue (2021–2026)
3.1.2 Global Hepatocellular Carcinoma Treatment Drug Revenue Market Share by Players (2021–2026)
3.2 Global Top Hepatocellular Carcinoma Treatment Drug Players Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
3.3 Global Key Players Ranking by Hepatocellular Carcinoma Treatment Drug Revenue
3.4 Global Hepatocellular Carcinoma Treatment Drug Market Concentration Ratio
3.4.1 Global Hepatocellular Carcinoma Treatment Drug Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Hepatocellular Carcinoma Treatment Drug Revenue in 2025
3.5 Global Key Players of Hepatocellular Carcinoma Treatment Drug Head Offices and Areas Served
3.6 Global Key Players of Hepatocellular Carcinoma Treatment Drug, Products and Applications
3.7 Global Key Players of Hepatocellular Carcinoma Treatment Drug, Date of General Availability (GA)
3.8 Mergers and Acquisitions, Expansion Plans
4 Hepatocellular Carcinoma Treatment Drug Breakdown Data by Type
4.1 Global Hepatocellular Carcinoma Treatment Drug Historic Market Size by Type (2021–2026)
4.2 Global Hepatocellular Carcinoma Treatment Drug Forecasted Market Size by Type (2027–2032)
5 Hepatocellular Carcinoma Treatment Drug Breakdown Data by Application
5.1 Global Hepatocellular Carcinoma Treatment Drug Historic Market Size by Application (2021–2026)
5.2 Global Hepatocellular Carcinoma Treatment Drug Forecasted Market Size by Application (2027–2032)
6 North America
6.1 North America Hepatocellular Carcinoma Treatment Drug Market Size (2021–2032)
6.2 North America Hepatocellular Carcinoma Treatment Drug Market Growth Rate by Country: 2021 vs 2025 vs 2032
6.3 North America Hepatocellular Carcinoma Treatment Drug Market Size by Country (2021–2026)
6.4 North America Hepatocellular Carcinoma Treatment Drug Market Size by Country (2027–2032)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Hepatocellular Carcinoma Treatment Drug Market Size (2021–2032)
7.2 Europe Hepatocellular Carcinoma Treatment Drug Market Growth Rate by Country: 2021 vs 2025 vs 2032
7.3 Europe Hepatocellular Carcinoma Treatment Drug Market Size by Country (2021–2026)
7.4 Europe Hepatocellular Carcinoma Treatment Drug Market Size by Country (2027–2032)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Ireland
8 Asia-Pacific
8.1 Asia-Pacific Hepatocellular Carcinoma Treatment Drug Market Size (2021–2032)
8.2 Asia-Pacific Hepatocellular Carcinoma Treatment Drug Market Growth Rate by Region: 2021 vs 2025 vs 2032
8.3 Asia-Pacific Hepatocellular Carcinoma Treatment Drug Market Size by Region (2021–2026)
8.4 Asia-Pacific Hepatocellular Carcinoma Treatment Drug Market Size by Region (2027–2032)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia & New Zealand
9 Latin America
9.1 Latin America Hepatocellular Carcinoma Treatment Drug Market Size (2021–2032)
9.2 Latin America Hepatocellular Carcinoma Treatment Drug Market Growth Rate by Country: 2021 vs 2025 vs 2032
9.3 Latin America Hepatocellular Carcinoma Treatment Drug Market Size by Country (2021–2026)
9.4 Latin America Hepatocellular Carcinoma Treatment Drug Market Size by Country (2027–2032)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Hepatocellular Carcinoma Treatment Drug Market Size (2021–2032)
10.2 Middle East & Africa Hepatocellular Carcinoma Treatment Drug Market Growth Rate by Country: 2021 vs 2025 vs 2032
10.3 Middle East & Africa Hepatocellular Carcinoma Treatment Drug Market Size by Country (2021–2026)
10.4 Middle East & Africa Hepatocellular Carcinoma Treatment Drug Market Size by Country (2027–2032)
10.5 Israel
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Merck & Co.
11.1.1 Merck & Co. Company Details
11.1.2 Merck & Co. Business Overview
11.1.3 Merck & Co. Hepatocellular Carcinoma Treatment Drug Introduction
11.1.4 Merck & Co. Revenue in Hepatocellular Carcinoma Treatment Drug Business (2021–2026)
11.1.5 Merck & Co. Recent Development
11.2 Bayer
11.2.1 Bayer Company Details
11.2.2 Bayer Business Overview
11.2.3 Bayer Hepatocellular Carcinoma Treatment Drug Introduction
11.2.4 Bayer Revenue in Hepatocellular Carcinoma Treatment Drug Business (2021–2026)
11.2.5 Bayer Recent Development
11.3 Roche
11.3.1 Roche Company Details
11.3.2 Roche Business Overview
11.3.3 Roche Hepatocellular Carcinoma Treatment Drug Introduction
11.3.4 Roche Revenue in Hepatocellular Carcinoma Treatment Drug Business (2021–2026)
11.3.5 Roche Recent Development
11.4 Eli Lilly and Company
11.4.1 Eli Lilly and Company Company Details
11.4.2 Eli Lilly and Company Business Overview
11.4.3 Eli Lilly and Company Hepatocellular Carcinoma Treatment Drug Introduction
11.4.4 Eli Lilly and Company Revenue in Hepatocellular Carcinoma Treatment Drug Business (2021–2026)
11.4.5 Eli Lilly and Company Recent Development
11.5 Bristol-Myers Squibb
11.5.1 Bristol-Myers Squibb Company Details
11.5.2 Bristol-Myers Squibb Business Overview
11.5.3 Bristol-Myers Squibb Hepatocellular Carcinoma Treatment Drug Introduction
11.5.4 Bristol-Myers Squibb Revenue in Hepatocellular Carcinoma Treatment Drug Business (2021–2026)
11.5.5 Bristol-Myers Squibb Recent Development
11.6 Exelixis Inc
11.6.1 Exelixis Inc Company Details
11.6.2 Exelixis Inc Business Overview
11.6.3 Exelixis Inc Hepatocellular Carcinoma Treatment Drug Introduction
11.6.4 Exelixis Inc Revenue in Hepatocellular Carcinoma Treatment Drug Business (2021–2026)
11.6.5 Exelixis Inc Recent Development
11.7 Innovent Biologics Inc
11.7.1 Innovent Biologics Inc Company Details
11.7.2 Innovent Biologics Inc Business Overview
11.7.3 Innovent Biologics Inc Hepatocellular Carcinoma Treatment Drug Introduction
11.7.4 Innovent Biologics Inc Revenue in Hepatocellular Carcinoma Treatment Drug Business (2021–2026)
11.7.5 Innovent Biologics Inc Recent Development
11.8 Akeso, Inc
11.8.1 Akeso, Inc Company Details
11.8.2 Akeso, Inc Business Overview
11.8.3 Akeso, Inc Hepatocellular Carcinoma Treatment Drug Introduction
11.8.4 Akeso, Inc Revenue in Hepatocellular Carcinoma Treatment Drug Business (2021–2026)
11.8.5 Akeso, Inc Recent Development
11.9 Jiangsu Hengrui Medicine Co Ltd
11.9.1 Jiangsu Hengrui Medicine Co Ltd Company Details
11.9.2 Jiangsu Hengrui Medicine Co Ltd Business Overview
11.9.3 Jiangsu Hengrui Medicine Co Ltd Hepatocellular Carcinoma Treatment Drug Introduction
11.9.4 Jiangsu Hengrui Medicine Co Ltd Revenue in Hepatocellular Carcinoma Treatment Drug Business (2021–2026)
11.9.5 Jiangsu Hengrui Medicine Co Ltd Recent Development
11.10 AstraZeneca Plc
11.10.1 AstraZeneca Plc Company Details
11.10.2 AstraZeneca Plc Business Overview
11.10.3 AstraZeneca Plc Hepatocellular Carcinoma Treatment Drug Introduction
11.10.4 AstraZeneca Plc Revenue in Hepatocellular Carcinoma Treatment Drug Business (2021–2026)
11.10.5 AstraZeneca Plc Recent Development
11.11 BeiGene
11.11.1 BeiGene Company Details
11.11.2 BeiGene Business Overview
11.11.3 BeiGene Hepatocellular Carcinoma Treatment Drug Introduction
11.11.4 BeiGene Revenue in Hepatocellular Carcinoma Treatment Drug Business (2021–2026)
11.11.5 BeiGene Recent Development
11.12 Sanofi SA
11.12.1 Sanofi SA Company Details
11.12.2 Sanofi SA Business Overview
11.12.3 Sanofi SA Hepatocellular Carcinoma Treatment Drug Introduction
11.12.4 Sanofi SA Revenue in Hepatocellular Carcinoma Treatment Drug Business (2021–2026)
11.12.5 Sanofi SA Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Hepatocellular Carcinoma Treatment Drug Market Size Growth Rate by Type (US$ Million): 2021 vs 2025 vs 2032
Table 2. Key Players of Targeted Therapy Drugs
Table 3. Key Players of Immune Checkpoint Inhibitors
Table 4. Key Players of Chemotherapy Drugs
Table 5. Global Hepatocellular Carcinoma Treatment Drug Market Size Growth Rate by Treatment Line (US$ Million): 2021 vs 2025 vs 2032
Table 6. Key Players of First-line HCC Therapy
Table 7. Key Players of Second-line HCC Therapy
Table 8. Key Players of Adjuvant Therapy
Table 9. Key Players of Palliative Drug Treatment
Table 10. Global Hepatocellular Carcinoma Treatment Drug Market Size Growth Rate by Administration Route (US$ Million): 2021 vs 2025 vs 2032
Table 11. Key Players of Oral HCC Drugs
Table 12. Key Players of Intravenous Infusion Drugs
Table 13. Key Players of Intra-arterial Chemotherapy Drugs
Table 14. Global Hepatocellular Carcinoma Treatment Drug Market Size Growth by Application (US$ Million): 2021 vs 2025 vs 2032
Table 15. Global Hepatocellular Carcinoma Treatment Drug Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 16. Global Hepatocellular Carcinoma Treatment Drug Market Size by Region (US$ Million), 2021–2026
Table 17. Global Hepatocellular Carcinoma Treatment Drug Market Share by Region (2021–2026)
Table 18. Global Hepatocellular Carcinoma Treatment Drug Forecasted Market Size by Region (US$ Million), 2027–2032
Table 19. Global Hepatocellular Carcinoma Treatment Drug Market Share by Region (2027–2032)
Table 20. Hepatocellular Carcinoma Treatment Drug Market Trends
Table 21. Hepatocellular Carcinoma Treatment Drug Market Drivers
Table 22. Hepatocellular Carcinoma Treatment Drug Market Challenges
Table 23. Hepatocellular Carcinoma Treatment Drug Market Restraints
Table 24. Global Hepatocellular Carcinoma Treatment Drug Revenue by Players (US$ Million), 2021–2026
Table 25. Global Hepatocellular Carcinoma Treatment Drug Market Share by Players (2021–2026)
Table 26. Global Top Hepatocellular Carcinoma Treatment Drug Players by Tier (Tier 1, Tier 2, and Tier 3), based on Hepatocellular Carcinoma Treatment Drug Revenue, 2025
Table 27. Ranking of Global Top Hepatocellular Carcinoma Treatment Drug Companies by Revenue (US$ Million) in 2025
Table 28. Global 5 Largest Players Market Share by Hepatocellular Carcinoma Treatment Drug Revenue (CR5 and HHI), 2021–2026
Table 29. Global Key Players of Hepatocellular Carcinoma Treatment Drug, Headquarters and Area Served
Table 30. Global Key Players of Hepatocellular Carcinoma Treatment Drug, Products and Applications
Table 31. Global Key Players of Hepatocellular Carcinoma Treatment Drug, Date of General Availability (GA)
Table 32. Mergers and Acquisitions, Expansion Plans
Table 33. Global Hepatocellular Carcinoma Treatment Drug Market Size by Type (US$ Million), 2021–2026
Table 34. Global Hepatocellular Carcinoma Treatment Drug Revenue Market Share by Type (2021–2026)
Table 35. Global Hepatocellular Carcinoma Treatment Drug Forecasted Market Size by Type (US$ Million), 2027–2032
Table 36. Global Hepatocellular Carcinoma Treatment Drug Revenue Market Share by Type (2027–2032)
Table 37. Global Hepatocellular Carcinoma Treatment Drug Market Size by Application (US$ Million), 2021–2026
Table 38. Global Hepatocellular Carcinoma Treatment Drug Revenue Market Share by Application (2021–2026)
Table 39. Global Hepatocellular Carcinoma Treatment Drug Forecasted Market Size by Application (US$ Million), 2027–2032
Table 40. Global Hepatocellular Carcinoma Treatment Drug Revenue Market Share by Application (2027–2032)
Table 41. North America Hepatocellular Carcinoma Treatment Drug Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 42. North America Hepatocellular Carcinoma Treatment Drug Market Size by Country (US$ Million), 2021–2026
Table 43. North America Hepatocellular Carcinoma Treatment Drug Market Size by Country (US$ Million), 2027–2032
Table 44. Europe Hepatocellular Carcinoma Treatment Drug Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 45. Europe Hepatocellular Carcinoma Treatment Drug Market Size by Country (US$ Million), 2021–2026
Table 46. Europe Hepatocellular Carcinoma Treatment Drug Market Size by Country (US$ Million), 2027–2032
Table 47. Asia-Pacific Hepatocellular Carcinoma Treatment Drug Market Size Growth Rate by Region (US$ Million): 2021 vs 2025 vs 2032
Table 48. Asia-Pacific Hepatocellular Carcinoma Treatment Drug Market Size by Region (US$ Million), 2021–2026
Table 49. Asia-Pacific Hepatocellular Carcinoma Treatment Drug Market Size by Region (US$ Million), 2027–2032
Table 50. Latin America Hepatocellular Carcinoma Treatment Drug Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 51. Latin America Hepatocellular Carcinoma Treatment Drug Market Size by Country (US$ Million), 2021–2026
Table 52. Latin America Hepatocellular Carcinoma Treatment Drug Market Size by Country (US$ Million), 2027–2032
Table 53. Middle East & Africa Hepatocellular Carcinoma Treatment Drug Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 54. Middle East & Africa Hepatocellular Carcinoma Treatment Drug Market Size by Country (US$ Million), 2021–2026
Table 55. Middle East & Africa Hepatocellular Carcinoma Treatment Drug Market Size by Country (US$ Million), 2027–2032
Table 56. Merck & Co. Company Details
Table 57. Merck & Co. Business Overview
Table 58. Merck & Co. Hepatocellular Carcinoma Treatment Drug Product
Table 59. Merck & Co. Revenue in Hepatocellular Carcinoma Treatment Drug Business (US$ Million), 2021–2026
Table 60. Merck & Co. Recent Development
Table 61. Bayer Company Details
Table 62. Bayer Business Overview
Table 63. Bayer Hepatocellular Carcinoma Treatment Drug Product
Table 64. Bayer Revenue in Hepatocellular Carcinoma Treatment Drug Business (US$ Million), 2021–2026
Table 65. Bayer Recent Development
Table 66. Roche Company Details
Table 67. Roche Business Overview
Table 68. Roche Hepatocellular Carcinoma Treatment Drug Product
Table 69. Roche Revenue in Hepatocellular Carcinoma Treatment Drug Business (US$ Million), 2021–2026
Table 70. Roche Recent Development
Table 71. Eli Lilly and Company Company Details
Table 72. Eli Lilly and Company Business Overview
Table 73. Eli Lilly and Company Hepatocellular Carcinoma Treatment Drug Product
Table 74. Eli Lilly and Company Revenue in Hepatocellular Carcinoma Treatment Drug Business (US$ Million), 2021–2026
Table 75. Eli Lilly and Company Recent Development
Table 76. Bristol-Myers Squibb Company Details
Table 77. Bristol-Myers Squibb Business Overview
Table 78. Bristol-Myers Squibb Hepatocellular Carcinoma Treatment Drug Product
Table 79. Bristol-Myers Squibb Revenue in Hepatocellular Carcinoma Treatment Drug Business (US$ Million), 2021–2026
Table 80. Bristol-Myers Squibb Recent Development
Table 81. Exelixis Inc Company Details
Table 82. Exelixis Inc Business Overview
Table 83. Exelixis Inc Hepatocellular Carcinoma Treatment Drug Product
Table 84. Exelixis Inc Revenue in Hepatocellular Carcinoma Treatment Drug Business (US$ Million), 2021–2026
Table 85. Exelixis Inc Recent Development
Table 86. Innovent Biologics Inc Company Details
Table 87. Innovent Biologics Inc Business Overview
Table 88. Innovent Biologics Inc Hepatocellular Carcinoma Treatment Drug Product
Table 89. Innovent Biologics Inc Revenue in Hepatocellular Carcinoma Treatment Drug Business (US$ Million), 2021–2026
Table 90. Innovent Biologics Inc Recent Development
Table 91. Akeso, Inc Company Details
Table 92. Akeso, Inc Business Overview
Table 93. Akeso, Inc Hepatocellular Carcinoma Treatment Drug Product
Table 94. Akeso, Inc Revenue in Hepatocellular Carcinoma Treatment Drug Business (US$ Million), 2021–2026
Table 95. Akeso, Inc Recent Development
Table 96. Jiangsu Hengrui Medicine Co Ltd Company Details
Table 97. Jiangsu Hengrui Medicine Co Ltd Business Overview
Table 98. Jiangsu Hengrui Medicine Co Ltd Hepatocellular Carcinoma Treatment Drug Product
Table 99. Jiangsu Hengrui Medicine Co Ltd Revenue in Hepatocellular Carcinoma Treatment Drug Business (US$ Million), 2021–2026
Table 100. Jiangsu Hengrui Medicine Co Ltd Recent Development
Table 101. AstraZeneca Plc Company Details
Table 102. AstraZeneca Plc Business Overview
Table 103. AstraZeneca Plc Hepatocellular Carcinoma Treatment Drug Product
Table 104. AstraZeneca Plc Revenue in Hepatocellular Carcinoma Treatment Drug Business (US$ Million), 2021–2026
Table 105. AstraZeneca Plc Recent Development
Table 106. BeiGene Company Details
Table 107. BeiGene Business Overview
Table 108. BeiGene Hepatocellular Carcinoma Treatment Drug Product
Table 109. BeiGene Revenue in Hepatocellular Carcinoma Treatment Drug Business (US$ Million), 2021–2026
Table 110. BeiGene Recent Development
Table 111. Sanofi SA Company Details
Table 112. Sanofi SA Business Overview
Table 113. Sanofi SA Hepatocellular Carcinoma Treatment Drug Product
Table 114. Sanofi SA Revenue in Hepatocellular Carcinoma Treatment Drug Business (US$ Million), 2021–2026
Table 115. Sanofi SA Recent Development
Table 116. Research Programs/Design for This Report
Table 117. Key Data Information from Secondary Sources
Table 118. Key Data Information from Primary Sources
Table 119. Authors List of This Report
List of Figures
Figure 1. Hepatocellular Carcinoma Treatment Drug Picture
Figure 2. Global Hepatocellular Carcinoma Treatment Drug Market Size Comparison by Type (US$ Million), 2021–2032
Figure 3. Global Hepatocellular Carcinoma Treatment Drug Market Share by Type: 2025 vs 2032
Figure 4. Targeted Therapy Drugs Features
Figure 5. Immune Checkpoint Inhibitors Features
Figure 6. Chemotherapy Drugs Features
Figure 7. Global Hepatocellular Carcinoma Treatment Drug Market Size Comparison by Treatment Line (US$ Million), 2021–2032
Figure 8. First-line HCC Therapy Features
Figure 9. Second-line HCC Therapy Features
Figure 10. Adjuvant Therapy Features
Figure 11. Palliative Drug Treatment Features
Figure 12. Global Hepatocellular Carcinoma Treatment Drug Market Size Comparison by Administration Route (US$ Million), 2021–2032
Figure 13. Oral HCC Drugs Features
Figure 14. Intravenous Infusion Drugs Features
Figure 15. Intra-arterial Chemotherapy Drugs Features
Figure 16. Global Hepatocellular Carcinoma Treatment Drug Market Size by Application (US$ Million), 2021–2032
Figure 17. Global Hepatocellular Carcinoma Treatment Drug Market Share by Application: 2025 vs 2032
Figure 18. Below 29 Years Case Studies
Figure 19. 30-49 Years Case Studies
Figure 20. Above 50 Years Case Studies
Figure 21. Hepatocellular Carcinoma Treatment Drug Report Years Considered
Figure 22. Global Hepatocellular Carcinoma Treatment Drug Market Size (US$ Million), Year-over-Year: 2021–2032
Figure 23. Global Hepatocellular Carcinoma Treatment Drug Market Size, (US$ Million), 2021 vs 2025 vs 2032
Figure 24. Global Hepatocellular Carcinoma Treatment Drug Market Share by Region: 2025 vs 2032
Figure 25. Global Hepatocellular Carcinoma Treatment Drug Market Share by Players in 2025
Figure 26. Global Hepatocellular Carcinoma Treatment Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 27. The Top 10 and 5 Players Market Share by Hepatocellular Carcinoma Treatment Drug Revenue in 2025
Figure 28. North America Hepatocellular Carcinoma Treatment Drug Market Size YoY Growth (US$ Million), 2021–2032
Figure 29. North America Hepatocellular Carcinoma Treatment Drug Market Share by Country (2021–2032)
Figure 30. United States Hepatocellular Carcinoma Treatment Drug Market Size YoY Growth (US$ Million), 2021–2032
Figure 31. Canada Hepatocellular Carcinoma Treatment Drug Market Size YoY Growth (US$ Million), 2021–2032
Figure 32. Europe Hepatocellular Carcinoma Treatment Drug Market Size YoY Growth (US$ Million), 2021–2032
Figure 33. Europe Hepatocellular Carcinoma Treatment Drug Market Share by Country (2021–2032)
Figure 34. Germany Hepatocellular Carcinoma Treatment Drug Market Size YoY Growth (US$ Million), 2021–2032
Figure 35. France Hepatocellular Carcinoma Treatment Drug Market Size YoY Growth (US$ Million), 2021–2032
Figure 36. U.K. Hepatocellular Carcinoma Treatment Drug Market Size YoY Growth (US$ Million), 2021–2032
Figure 37. Italy Hepatocellular Carcinoma Treatment Drug Market Size YoY Growth (US$ Million), 2021–2032
Figure 38. Russia Hepatocellular Carcinoma Treatment Drug Market Size YoY Growth (US$ Million), 2021–2032
Figure 39. Ireland Hepatocellular Carcinoma Treatment Drug Market Size YoY Growth (US$ Million), 2021–2032
Figure 40. Asia-Pacific Hepatocellular Carcinoma Treatment Drug Market Size YoY Growth (US$ Million), 2021–2032
Figure 41. Asia-Pacific Hepatocellular Carcinoma Treatment Drug Market Share by Region (2021–2032)
Figure 42. China Hepatocellular Carcinoma Treatment Drug Market Size YoY Growth (US$ Million), 2021–2032
Figure 43. Japan Hepatocellular Carcinoma Treatment Drug Market Size YoY Growth (US$ Million), 2021–2032
Figure 44. South Korea Hepatocellular Carcinoma Treatment Drug Market Size YoY Growth (US$ Million), 2021–2032
Figure 45. Southeast Asia Hepatocellular Carcinoma Treatment Drug Market Size YoY Growth (US$ Million), 2021–2032
Figure 46. India Hepatocellular Carcinoma Treatment Drug Market Size YoY Growth (US$ Million), 2021–2032
Figure 47. Australia & New Zealand Hepatocellular Carcinoma Treatment Drug Market Size YoY Growth (US$ Million), 2021–2032
Figure 48. Latin America Hepatocellular Carcinoma Treatment Drug Market Size YoY Growth (US$ Million), 2021–2032
Figure 49. Latin America Hepatocellular Carcinoma Treatment Drug Market Share by Country (2021–2032)
Figure 50. Mexico Hepatocellular Carcinoma Treatment Drug Market Size YoY Growth (US$ Million), 2021–2032
Figure 51. Brazil Hepatocellular Carcinoma Treatment Drug Market Size YoY Growth (US$ Million), 2021–2032
Figure 52. Middle East & Africa Hepatocellular Carcinoma Treatment Drug Market Size YoY Growth (US$ Million), 2021–2032
Figure 53. Middle East & Africa Hepatocellular Carcinoma Treatment Drug Market Share by Country (2021–2032)
Figure 54. Israel Hepatocellular Carcinoma Treatment Drug Market Size YoY Growth (US$ Million), 2021–2032
Figure 55. Saudi Arabia Hepatocellular Carcinoma Treatment Drug Market Size YoY Growth (US$ Million), 2021–2032
Figure 56. UAE Hepatocellular Carcinoma Treatment Drug Market Size YoY Growth (US$ Million), 2021–2032
Figure 57. Merck & Co. Revenue Growth Rate in Hepatocellular Carcinoma Treatment Drug Business (2021–2026)
Figure 58. Bayer Revenue Growth Rate in Hepatocellular Carcinoma Treatment Drug Business (2021–2026)
Figure 59. Roche Revenue Growth Rate in Hepatocellular Carcinoma Treatment Drug Business (2021–2026)
Figure 60. Eli Lilly and Company Revenue Growth Rate in Hepatocellular Carcinoma Treatment Drug Business (2021–2026)
Figure 61. Bristol-Myers Squibb Revenue Growth Rate in Hepatocellular Carcinoma Treatment Drug Business (2021–2026)
Figure 62. Exelixis Inc Revenue Growth Rate in Hepatocellular Carcinoma Treatment Drug Business (2021–2026)
Figure 63. Innovent Biologics Inc Revenue Growth Rate in Hepatocellular Carcinoma Treatment Drug Business (2021–2026)
Figure 64. Akeso, Inc Revenue Growth Rate in Hepatocellular Carcinoma Treatment Drug Business (2021–2026)
Figure 65. Jiangsu Hengrui Medicine Co Ltd Revenue Growth Rate in Hepatocellular Carcinoma Treatment Drug Business (2021–2026)
Figure 66. AstraZeneca Plc Revenue Growth Rate in Hepatocellular Carcinoma Treatment Drug Business (2021–2026)
Figure 67. BeiGene Revenue Growth Rate in Hepatocellular Carcinoma Treatment Drug Business (2021–2026)
Figure 68. Sanofi SA Revenue Growth Rate in Hepatocellular Carcinoma Treatment Drug Business (2021–2026)
Figure 69. Bottom-up and Top-down Approaches for This Report
Figure 70. Data Triangulation
Figure 71. Key Executives Interviewed
